EPO and chronic kidney disease: Second, since some recent clinical reports suggested that EPO is also produced by the adult liver of CKD patients in compensation for the renal functional loss, as evidenced by the presence of the liver-specific glycosylation pattern in circulating EPO7,42, the liver can be a possible target organ in the development of novel therapeutic agents for renal anemia.